TY - JOUR
T1 - Combining transgenesis with paratransgenesis to fight malaria
AU - Huang, Wei
AU - Vega-Rodriguez, Joel
AU - Kizito, Chritopher
AU - Cha, Sung Jae
AU - Jacobs-Lorena, Marcelo
N1 - Funding Information:
We thank the Insectary and Parasite Core Facilities of the Johns Hopkins Malaria Research Institute. This work was supported by a grant R01AI031478 from the National Institutes of Health and by the Bloomberg Philanthropies. Supply of human blood was supported by the National Institutes of Health grant RR00052. We thank Dr. Yuemei Dong from the Johns Hopkins Malaria Research Institute for providing the helper plasmid and Dr. Christopher Potter from Johns Hopkins School of Medicine for providing pXL-BACIIECFP-15XQUAS-TATA-PAI-SV40 and pXL-BACII-DsRed-AAPP-QF2-hsp70 plasmids.
Publisher Copyright:
© 2022, eLife Sciences Publications Ltd. All rights reserved.
PY - 2022
Y1 - 2022
N2 - Malaria is among the deadliest infectious diseases, and Plasmodium, the causative agent, needs to complete a complex development cycle in its vector mosquito for transmission to occur. Two promising strategies to curb transmission are transgenesis, consisting of genetically engineering mosquitoes to express antimalarial effector molecules, and paratransgenesis, consisting of introducing into the mosquito commensal bacteria engineered to express antimalarial effector molecules. Although both approaches restrict parasite development in the mosquito, it is not known how their effectiveness compares. Here we provide an in-depth assessment of transgenesis and paratransgenesis and evaluate the combination of the two approaches. Using the Q-system to drive gene expression, we engineered mosquitoes to produce and secrete two effectors – scorpine and the MP2 peptide – into the mosquito gut and salivary glands. We also engineered Serratia, a commensal bacterium capable of spreading through mosquito populations to secrete effectors into the mosquito gut. Whereas both mosquito-based and bacteria-based approaches strongly reduced the oocyst and sporozoite intensity, a substantially stronger reduction of Plasmodium falciparum development was achieved when transgenesis and paratransgenesis were combined. Most impor-tantly, transmission of Plasmodium berghei from infected to naïve mice was maximally inhibited by the combination of the two approaches. Combining these two strategies promises to become a powerful approach to combat malaria.
AB - Malaria is among the deadliest infectious diseases, and Plasmodium, the causative agent, needs to complete a complex development cycle in its vector mosquito for transmission to occur. Two promising strategies to curb transmission are transgenesis, consisting of genetically engineering mosquitoes to express antimalarial effector molecules, and paratransgenesis, consisting of introducing into the mosquito commensal bacteria engineered to express antimalarial effector molecules. Although both approaches restrict parasite development in the mosquito, it is not known how their effectiveness compares. Here we provide an in-depth assessment of transgenesis and paratransgenesis and evaluate the combination of the two approaches. Using the Q-system to drive gene expression, we engineered mosquitoes to produce and secrete two effectors – scorpine and the MP2 peptide – into the mosquito gut and salivary glands. We also engineered Serratia, a commensal bacterium capable of spreading through mosquito populations to secrete effectors into the mosquito gut. Whereas both mosquito-based and bacteria-based approaches strongly reduced the oocyst and sporozoite intensity, a substantially stronger reduction of Plasmodium falciparum development was achieved when transgenesis and paratransgenesis were combined. Most impor-tantly, transmission of Plasmodium berghei from infected to naïve mice was maximally inhibited by the combination of the two approaches. Combining these two strategies promises to become a powerful approach to combat malaria.
UR - http://www.scopus.com/inward/record.url?scp=85140559036&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140559036&partnerID=8YFLogxK
U2 - 10.7554/eLife.77584
DO - 10.7554/eLife.77584
M3 - Article
C2 - 36281969
AN - SCOPUS:85140559036
SN - 2050-084X
VL - 11
JO - eLife
JF - eLife
M1 - e77584
ER -